Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | GPR39 | O43194 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556727 | 0.80 | REN (0.67) | RENKCNH2CYP3A4 | |
| SCHEMBL557049 | 0.78 | FNTA (0.35) | RENKCNH2 | |
| SCHEMBL7868962 | 0.78 | REN (1.00) | RENKCNH2CYP3A4P2RX7 | |
| SCHEMBL556066 | 0.78 | REN (1.00) | RENKCNH2CYP3A4P2RX7 | |
| SCHEMBL555467 | 0.77 | REN (0.61) | RENKCNH2CYP3A4CD274NAMPT | |
| SCHEMBL555694 | 0.71 | REN (0.85) | RENKCNH2CYP3A4 | |
| SCHEMBL10202449 | 0.71 | REN (0.85) | RENKCNH2CYP3A4 | |
| SCHEMBL534916 | 0.70 | REN (0.54) | RENKCNH2CYP3A4CD274GPR39 | |
| SCHEMBL557571 | 0.69 | REN (0.41) | RENKCNH2CYP3A4NAMPTKDM6B | |
| SCHEMBL556060 | 0.68 | REN (0.45) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.